Li Di

Chang Chun Street
Beijing, 100053, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.

Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.

Journal: Journal of neurology

Published: November 20, 2025

Clinical and laboratory features of juvenile-onset anti-NF155 autoimmune nodopathy.

Clinical and laboratory features of juvenile-onset anti-NF155 autoimmune nodopathy.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: September 26, 2025

Association of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross-Sectional Study.

Association of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross-Sectional Study.

Journal: CNS neuroscience & therapeutics

Published: July 25, 2025

Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study.

Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study.

Journal: ImmunoTargets and therapy

Published: June 06, 2025

Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety.

Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety.

Journal: CNS neuroscience & therapeutics

Published: May 24, 2025

Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.

Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.

Journal: Journal of neurology

Published: April 29, 2025

Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.

Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.

Journal: CNS neuroscience & therapeutics

Published: April 14, 2025

Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis.

Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis.

Journal: Journal of autoimmunity

Published: February 24, 2025

Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.

Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.

Journal: Annals of neurology

Published: February 04, 2025

Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China.

Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China.

Journal: CNS neuroscience & therapeutics

Published: November 01, 2024

Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients.

Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients.

Journal: Therapeutic advances in neurological disorders

Published: October 01, 2024

The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.

The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.

Journal: Vaccines

Published: September 24, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026